107220-28-0

Usage

Uses

Used in Pharmaceutical Industry:
Cevimeline Hydrochloride Salt is used as a therapeutic agent for the treatment of dry mouth (xerostomia) and other conditions related to reduced salivary gland function. Its agonistic action on muscarinic M1 and M3 receptors promotes increased saliva production, providing relief and improving the quality of life for patients suffering from these conditions.
Additionally, due to its muscarinic receptor agonist properties, Cevimeline Hydrochloride Salt may also have potential applications in other areas of medicine, such as the treatment of gastrointestinal disorders or cognitive impairments, although these uses would require further research and clinical validation.

Biological Activity

Selective M 1 receptor agonist. Induces atropine-sensitive contractions of isolated guinea pig ilea and trachea preparations (EC 50 values are 3.5 and 3 μ M respectively). Reverses AF64A-induced cognitive impairments in vivo .

Upstream product

• 107220-27-9 2’-methylspiro{1-azabicyclo [2.2.2]octane-3,5'[1,3]oxathiolane} 
• 107220-26-8 3-hydroxy-3-(mercaptomethyl)quinuclidine 
• 75-07-0 acetaldehyde 
• 64168-68-9 Spiro- Hydrochlorid 
• 41353-91-7 1’-azaspiro[oxirane-2,3’-bicyclo[2.2.2]octane] 
• 1193-65-3 3-quinuclidinone hydrochloride 
• 1435450-21-7 C₉H₁₃NO₂S 
• 1435450-13-7 C₈H₁₄BrNO*BrH 
• 534-15-6 1,1-dimethoxyethane 
• 1067881-02-0 3-hydroxy-3-acetoxymercaptomethylquiniclidine thiolacetate 
• 107220-27-9 trans-cevimeline 

Relevant academic research and scientific papers

A new route to cevimeline

The present work demonstrates a new route for the synthesis of cevimeline in which safe and odorless thiourea is utilized as a thiolating reagent.

PROCESS FOR THE PREPARATION OF CIS-2-METHYLSPIRO (1, 3-OXATHIOLANE 5-3') QUINUCLIDINE

Methods are provided for making pharmaceutical-grade cis-2-methylspiro(1,3-oxathiolane-5,3′)quinuclidine and pharmaceutically acceptable salts thereof by isomerizing racemic 2-methylspiro(1,3-oxathiolane-5,3′)quinuclidine to cis-2-methylspiro(1,3-oxathiolane-5,3′)quinuclidine and subsequent purification of the C-MSOQ by salt formation with inexpensive and commercially available material such as sulfuric acid. Purification methods are disclosed which employ an organic solvent/water system and recrystallization with an organic solvent such as acetone.

OPHTHALMIC PERCUTANEOUSLY ABSORBED PREPARATION CONTAINING MUSCARINIC RECEPTOR AGONIST

A percutaneous absorption type ophthalmic preparation comprising muscarinic receptor agonist is prepared, which can promote lacrimal fluid secretion by administration to the skin surface of the eyelid, and which causes fewer side effects such as miosis, thereby to provide a percutaneous absorption type ophthalmic preparation capable of maintaining a therapeutically effective concentration of a muscarinic receptor agonist for promoting lacrimal fluid secretion, which is associated with fewer side effects such as miosis, and a method of promoting lacrimal fluid secretion by administering a percutaneous absorption type ophthalmic preparation containing a muscarinic receptor agonist to the skin surface of the eyelid.